Carboplatin + Etoposide + Ifosfamide + Pembrolizumab
Phase 2UNKNOWNDevelopment Stage
Lymphocyte-Rich Classical Hodgkin Lymphoma
Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
Apr 21, 2017 → Dec 1, 2024
About Carboplatin + Etoposide + Ifosfamide + Pembrolizumab
Carboplatin + Etoposide + Ifosfamide + Pembrolizumab is a phase 2 stage product being developed by Merck for Lymphocyte-Rich Classical Hodgkin Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03077828. Target conditions include Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03077828 | Phase 2 | UNKNOWN |